News & Updates
PharmEnable Therapeutics and Sosei Heptares Expand Drug Discovery Collaboration
PharmEnable Therapeutics and Sosei Heptares Expand Drug Discovery Collaboration The collaboration combines Sosei Heptares’ leading structure-based drug design platform with PharmEnable’s advanced artificial intelligence-enabled platform for designing high quality...
PharmEnable Closes $7.5M Financing led by MP Healthcare
PharmEnable Closes $7.5M Financing led by MP Healthcare to Develop Next Generation of Small Molecule Drugs to Treat Cancer and Neurological Diseases $7.5M Pre-Series A financing led by new investor MP Healthcare, the venture arm of Mitsubishi Tanabe Pharma Group....
Complex and structurally diverse: the next generation of small molecules
Small molecule drug discovery programmes often use commercial or proprietary compound libraries: a broad collection of molecules that are built by combining a wide variety of synthetically tractable building blocks. With such an extensive array of combinatorial...
PharmEnable announces multi-target collaboration with Denali Therapeutics in neurodegenerative disease
The strategic collaboration aims to accelerate drug discovery in neurodegenerative disease Joint research programmes against multiple undisclosed targets to be initiated over the next two years PharmEnable to receive an upfront cash payment and potential milestone...
PharmEnable awarded PLG Collaboration Deal of the Year Award
We are delighted that our business development team has been recognised with the prestigious Collaboration Deal of the Year Award by the Pharmaceutical Licensing Group for our shared-risk collaboration with Sosei Heptares, an international biopharmaceutical group. The...
How an AI drug discovery collaboration between Sosei Heptares and PharmEnable is accelerating complex science: generating new hit molecules against a difficult GPCR target
Artificial Intelligence (AI) is becoming an increasingly important part of drug discovery – as demonstrated by the significant progress in the ongoing collaboration between Sosei Heptares and PharmEnable focused on a challenging peptidergic G protein-coupled receptor...
PharmEnable selected for Tech Nation’s programme Applied AI 3.0
PharmEnable has been selected to join Applied AI 3.0, an established 5-month programme aimed at accelerating the growth of successful startups in AI. Delivered by the team at Tech Nation, the cohort is comprised of early-stage UK tech companies applying AI in...
PharmEnable and LifeArc partner to discover novel oral antiviral drugs to treat coronaviruses
PharmEnable is delighted to announce that it has entered into a drug discovery collaboration with LifeArc, an independent UK medical research charity, to apply their respective technologies and expertise to discover novel oral antiviral drugs with activity against...
In focus: Unlocking the potential of GPCR targets
GPCR representation, the tertiary structure of bovine rhodopsin within the cell membrane (in grey). Source: Wikimedia Commons PharmEnable has recently partnered with Sosei Heptares to work on a challenging G protein-coupled receptor (GPCR) target for a neurology...
PharmEnable wins Rising Star at UKBAA Angel Investment Award
We are delighted to announce that PharmEnable has been awarded Rising Star in the DeepTech Investment of the Year category at the UKBAA Angel Investment Awards 2021. The annual UKBAA Angel Investment awards, sponsored by Playfair Capital, recognise acknowledge the...
